يعرض 1 - 20 نتائج من 136 نتيجة بحث عن '"Bharmal, M"', وقت الاستعلام: 0.45s تنقيح النتائج
  1. 1
    Academic Journal
    Predictive and Interpretable Machine Learning of Economic Burden: The Role of Chronic Conditions Among Elderly Patients with Incident Primary Merkel Cell Carcinoma (MCC)

    المؤلفون: Mbous YPV, Siddiqui ZA, Bharmal M, LeMasters T, Kolodney J, Kelley GA, Kamal KM, Sambamoorthi U

    المصدر: ClinicoEconomics and Outcomes Research, Vol Volume 16, Pp 847-868 (2024)

    مصطلحات موضوعية: merkel cell carcinoma, out-of-pocket expenditures, economic burden, cancer care, chronic conditions, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950

    وصف الملف: electronic resource

    Relation: https://www.dovepress.com/predictive-and-interpretable-machine-learning-of-economic-burden-the-r-peer-reviewed-fulltext-article-CEOR; https://doaj.org/toc/1178-6981

    URL الوصول: https://doaj.org/article/f9a043f7310546a397672f4897ab5b04

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  2. 2
    Academic Journal
    Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)

    المؤلفون: Doshi GK, Bhanegaonkar A, Kearney M, Bharmal M, Cislo P, Kim R, Boyd M, Aguilar KM, Phatak H

    المصدر: ClinicoEconomics and Outcomes Research, Vol Volume 12, Pp 645-656 (2020)

    مصطلحات موضوعية: urothelial carcinoma, spear-bladder, real-world clinical outcomes, treatment sequencing, retrospective, community oncology setting, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950

    وصف الملف: electronic resource

    Relation: https://www.dovepress.com/treatment-sequencing-patterns-in-patients-with-metastatic-urothelial-c-peer-reviewed-article-CEOR; https://doaj.org/toc/1178-6981

    URL الوصول: https://doaj.org/article/5081f6bb473447ba86148d4bd4bfc034

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  3. 3
    Academic Journal
    P36 Can Real-World Evidence (RWE) Drive European, UK, and US Payer Decisions in the Reassessment of Oncology Therapies?

    المؤلفون: Bharmal, M, Katsoulis, I, Chang, J, Graham, A, Palencia, R, Stavropoulou, A, Pashos, C

    المصدر: Value in Health ; volume 25, issue 12, page S9 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2022.09.048
    https://api.elsevier.com/content/article/PII:S1098301522022501?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301522022501?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  4. 4
    Academic Journal
    PCR131 Patient and Caregiver Perception of Treatments for Locally Advanced or Metastatic Bladder Cancer: Insights from Social Media in the US

    المؤلفون: Bharmal, M, Loussikian, P, Marrel, A, Barbier, V, Arnould, B, Foulquié, P, Mebarki, A, Schück, S, Renner, S

    المصدر: Value in Health ; volume 25, issue 7, page S566 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2022.04.1474
    https://api.elsevier.com/content/article/PII:S1098301522016758?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301522016758?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  5. 5
    Academic Journal
    POSA243 Approaches to Immune Checkpoint Inhibitor (ICI) First-Line Maintenance Therapy (1L-MT) in Unresectable Locally Advanced (LA) or Metastatic Urothelial Cancer (mUC) in France, Germany, Italy, Spain, and the UK (EU5)

    المؤلفون: Milloy, N, Berry, M, Kostikas, M, Li, S, Kearney, M, Bharmal, M, Costa, N, Chang, J

    المصدر: Value in Health ; volume 25, issue 1, page S156 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2021.11.758
    https://api.elsevier.com/content/article/PII:S1098301521025535?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301521025535?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  6. 6
    Academic Journal
    Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives

    المؤلفون: Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M

    المصدر: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 659-672 (2019)

    مصطلحات موضوعية: urothelial carcinoma, budget impact model, cost analysis, economic analysis, immuno-oncology, chemotherapy, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950

    وصف الملف: electronic resource

    Relation: https://www.dovepress.com/budget-impact-of-including-avelumab-as-a-second-line-treatment-for-loc-peer-reviewed-article-CEOR; https://doaj.org/toc/1178-6981

    URL الوصول: https://doaj.org/article/a05ffa0ad64d4ab9bc91f472eae8250d

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  7. 7
    Academic Journal
    Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

    المؤلفون: Bharmal M, Kearney M, Zheng Y, Phatak H

    المصدر: ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 349-359 (2019)

    مصطلحات موضوعية: metastatic merkel cell carcinoma, cost, budget impact model, avelumab, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950

    وصف الملف: electronic resource

    Relation: https://www.dovepress.com/budget-impact-model-of-avelumab-in-patients-with-metastatic-merkel-cel-peer-reviewed-article-CEOR; https://doaj.org/toc/1178-6981

    URL الوصول: https://doaj.org/article/5ec3f3eb050f4570a86a4df0eb3a33d9

    View record in DOAJ Full Text Finder

    أضف إلى المفضلة
  8. 8
    Academic Journal
    What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches

    المؤلفون: Hatswell, A.J., Bullement, A., Schlichting, M., Bharmal, M.

    وصف الملف: text

    Relation: https://eprints.whiterose.ac.uk/169375/1/Hatswell2020_Article_WhatIsTheImpactOfTheAnalysisMe.pdf; Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972 , Schlichting, M. et al. (1 more author) (2021) What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Applied Health Economics and Health Policy, 19 (3). pp. 389-401. ISSN 1175-5652

    الاتاحة: https://eprints.whiterose.ac.uk/169375/
    https://eprints.whiterose.ac.uk/169375/1/Hatswell2020_Article_WhatIsTheImpactOfTheAnalysisMe.pdf

    View record in BASE

    أضف إلى المفضلة
  9. 9
    Academic Journal
    Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection

    المؤلفون: Bullement, A, Willis, A, Amin, A, Schlichting, M, Hatswell, AJ, Bharmal, M

    المصدر: BMC Medical Research Methodology , 20 (1) , Article 103. (2020)

    وصف الملف: text

    Relation: https://discovery.ucl.ac.uk/id/eprint/10101175/1/Evaluation%20of%20survival%20extrapolation%20in%20immuno-oncology%20using%20multiple%20pre-planned%20data%20cuts%20learnings%20to%20aid%20in%20model%20selec.pdf; https://discovery.ucl.ac.uk/id/eprint/10101175/

    الاتاحة: https://discovery.ucl.ac.uk/id/eprint/10101175/1/Evaluation%20of%20survival%20extrapolation%20in%20immuno-oncology%20using%20multiple%20pre-planned%20data%20cuts%20learnings%20to%20aid%20in%20model%20selec.pdf
    https://discovery.ucl.ac.uk/id/eprint/10101175/

    View record in BASE

    أضف إلى المفضلة
  10. 10
    Academic Journal
    Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection

    المؤلفون: Bullement, A., Willis, A., Amin, A., Schlichting, M., Hatswell, A.J., Bharmal, M.

    وصف الملف: text

    Relation: https://eprints.whiterose.ac.uk/161061/1/Evaluation%20of%20survival%20extrapolation%20in%20immuno-oncology%20using%20multiple%20pre-planned%20data%20cuts%20learnings%20to%20aid%20in%20model%20selec.pdf; Bullement, A. orcid.org/0000-0001-7091-0972 , Willis, A., Amin, A. et al. (3 more authors) (2020) Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 20. 103. ISSN 1471-2288

    الاتاحة: https://eprints.whiterose.ac.uk/161061/
    https://eprints.whiterose.ac.uk/161061/1/Evaluation%20of%20survival%20extrapolation%20in%20immuno-oncology%20using%20multiple%20pre-planned%20data%20cuts%20learnings%20to%20aid%20in%20model%20selec.pdf

    View record in BASE

    أضف إلى المفضلة
  11. 11
    Academic Journal
    1092P Non-progression with avelumab treatment in patients with metastatic Merkel cell carcinoma (mMCC) is associated with a clinically meaningful better health-related quality of life compared with progressive disease

    المؤلفون: Bharmal, M., Nolte, S., Lebbé, C., Mortier, L., Brohl, A.S., Fazio, N., Grob, J-J., Prinzi, N., Hanna, G.J., Hassel, J., Kiecker, F., Ellers-Lenz, B., Bajars, M., Guezel, G., Nghiem, P., Hunger, M., Schlichting, M., Henry-Szatkowski, M., D'Angelo, S.

    المصدر: Annals of Oncology ; volume 31, page S740-S741 ; ISSN 0923-7534

    الاتاحة: http://dx.doi.org/10.1016/j.annonc.2020.08.1216
    https://api.elsevier.com/content/article/PII:S0923753420412128?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S0923753420412128?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  12. 12
    Academic Journal
    PCN8 COMPARING PATIENT-RELEVANT ENDPOINT WITH CLINICAL ENDPOINT IN A RARE DISEASE: THE CASE OF METASTATIC MERKEL CELL CARCINOMA TREATED WITH AVELUMAB

    المؤلفون: Bharmal, M., Nolte, S., Lebbe, C., Mortier, L., Brohl, A.S., Fazio, N., Grob, J.J., Pusceddu, S., Hanna, G.J., Hassel, J.C., Kiecker, F., Ellers-Lenz, B., Bajars, M., Güzel, G., Nghiem, P., Hunger, M., Schlichting, M., Henry-Szatkowski, M., D'Angelo, S.P.

    المصدر: Value in Health ; volume 23, page S23 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2020.04.1515
    https://api.elsevier.com/content/article/PII:S109830152031740X?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S109830152031740X?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  13. 13
    Academic Journal
    Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma

    المؤلفون: Bullement, A, Nathan, P, Willis, A, Amin, A, Lilley, C, Stapelkamp, C, Hatswell, A, Pescott, C, Bharmal, M

    المصدر: PharmacoEconomics - Open , 3 pp. 377-390. (2019)

    وصف الملف: text

    Relation: https://discovery.ucl.ac.uk/id/eprint/10067291/1/Bullement2019_Article_CostEffectivenessOfAvelumabFor.pdf; https://discovery.ucl.ac.uk/id/eprint/10067291/

    الاتاحة: https://discovery.ucl.ac.uk/id/eprint/10067291/1/Bullement2019_Article_CostEffectivenessOfAvelumabFor.pdf
    https://discovery.ucl.ac.uk/id/eprint/10067291/

    View record in BASE

    أضف إلى المفضلة
  14. 14
    Academic Journal
    Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma

    المؤلفون: Bullement, A., Nathan, P., Willis, A., Amin, A., Lilley, C., Stapelkamp, C., Hatswell, A., Pescott, C., Bharmal, M.

    وصف الملف: text

    Relation: https://eprints.whiterose.ac.uk/169366/1/Cost%20Effectiveness%20of%20Avelumab%20for%20Metastatic%20Merkel%20Cell%20Carcinoma.pdf; Bullement, A. orcid.org/0000-0001-7091-0972 , Nathan, P., Willis, A. et al. (6 more authors) (2019) Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma. PharmacoEconomics - Open, 3 (3). pp. 377-390. ISSN 2509-4262

    الاتاحة: https://eprints.whiterose.ac.uk/169366/
    https://eprints.whiterose.ac.uk/169366/1/Cost%20Effectiveness%20of%20Avelumab%20for%20Metastatic%20Merkel%20Cell%20Carcinoma.pdf

    View record in BASE

    أضف إلى المفضلة
  15. 15
    Academic Journal
    Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data

    المؤلفون: D’Angelo, S.P., Nolte, S., Schlichting, M., Henry-Szatkowski, M., Hennessy, M., Bharmal, M.

    المصدر: Annals of Oncology ; volume 30, page v538 ; ISSN 0923-7534

    الاتاحة: http://dx.doi.org/10.1093/annonc/mdz255.009
    https://api.elsevier.com/content/article/PII:S0923753419595308?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S0923753419595308?httpAccept=text/plain
    http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz255.009/30086801/mdz255.009.pdf

    View record in BASE

    أضف إلى المفضلة
  16. 16
    Academic Journal
    ON4 REVIEW OF THE APPLICATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) DATA IN RECENT HEALTH TECHNOLOGY ASSESSMENTS (HTAS) OF CANCER IMMUNOTHERAPIES (IOS) BY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    المؤلفون: Bullement, A., Shields, G., Hatswell, A.J., Schlichting, M., Bharmal, M.

    المصدر: Value in Health ; volume 22, page S44 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.04.066
    https://api.elsevier.com/content/article/PII:S109830151930258X?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S109830151930258X?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  17. 17
    Academic Journal
    PCN259 SHOULD HEALTH STATE UTILITY VALUES (HSUVS) IN CANCER IMMUNOTHERAPIES (IOS) BE ANALYZED BY TIME TO DEATH (TTD) OR PROGRESSION STATUS? RESULTS OF A SIMULATION STUDY

    المؤلفون: Hatswell, A.J., Bullement, A., Schlichting, M., Bharmal, M.

    المصدر: Value in Health ; volume 22, page S105 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.04.380
    https://api.elsevier.com/content/article/PII:S1098301519305728?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519305728?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  18. 18
    Academic Journal
    PCN483 CONFIRMING THE PSYCHOMETRIC PERFORMANCE OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY–MELANOMA (FACT-M) QUESTIONNAIRE IN PATIENTS WITH MERKEL CELL CARCINOMA (MCC)

    المؤلفون: Bharmal, M., Nolte, S., Henry-Szatkowski, M., Hennessy, M., Schlichting, M.

    المصدر: Value in Health ; volume 22, page S531 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2019.09.675
    https://api.elsevier.com/content/article/PII:S1098301519330530?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301519330530?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  19. 19
    Academic Journal
    P48 Oncologists’ and Urologists’ Preferences for First-Line (1L) Treatment of Locally Advanced/Unresectable Metastatic Urothelial Carcinoma (AUC): A Discrete Choice Experiment (DCE) Conducted in 5 European Countries

    المؤلفون: Panattoni, L., Kearney, M., Land, N., Flottemesch, T., Sullivan, P., Kirker, M., Bharmal, M., Hauber, B.

    المصدر: Value in Health ; volume 26, issue 6, page S11 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2023.03.059
    https://api.elsevier.com/content/article/PII:S1098301523001596?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301523001596?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
  20. 20
    Academic Journal
    HPR107 Landscape of Value-Based Contracting in Oncology

    المؤلفون: Sharma, M., Agrawal, N., Khurana, V., Bharmal, M.

    المصدر: Value in Health ; volume 26, issue 6, page S230 ; ISSN 1098-3015

    الاتاحة: http://dx.doi.org/10.1016/j.jval.2023.03.1254
    https://api.elsevier.com/content/article/PII:S1098301523013542?httpAccept=text/xml
    https://api.elsevier.com/content/article/PII:S1098301523013542?httpAccept=text/plain

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء